With a 5.0-star rating on Google based on over 250 reviews, Movement Room is frequently recommended as one of the top choices ...

CEPI and POP BIO are committed to enabling equitable access to the outputs of their partnership, in line with CEPI’s ...

The Celcuity management team will host a webcast/conference call on Monday, July 28, 2025 at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like to ...

Dr. Shaltiel will present the Company’s exosome-based regenerative therapy platform at the Falling Walls Science Summit, taking place in Berlin, Germany from November 6-9, 2025. The winner, selected ...

Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are ...

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel ...

The Company intends to use the net proceeds from the Offering to pay $1,500,000 for marketing and advertising services to be provided by IR Agency LLC, $1,000,000 to fund the initial milestone payment ...

Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis ...

Liminatus is working in close coordination with experienced legal, financial, and regulatory advisors to determine the optimal structure, governance, and compliance framework for the proposed ...

Slated to open in mid-2026, the 60,000 square-foot Class-A industrial facility will significantly expand Nelipak’s regional capacity and capabilities. The new site will be ISO 13485 certified and ...

The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful ...

The transaction is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund ...